961.14(2)(ey) (ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
961.14(2)(f) (f) Clonitazene;
961.14(2)(fe) (fe) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
Effective date note NOTE: This paragraph was created eff. 9-9-17 by the creation of s. CSB 2.57, Wis. Adm. Code, by emergency rule EmR1716 under s. 961.11 (4m). EmR1716 expires 9-6-18 unless replaced sooner by the creation of s. CSB 2.57 by permanent rule.
961.14(2)(fm) (fm) Dextromoramide;
961.14(2)(gm) (gm) Diampromide;
961.14(2)(h) (h) Diethylthiambutene;
961.14(2)(hg) (hg) Difenoxin;
961.14(2)(hm) (hm) Dimenoxadol;
961.14(2)(j) (j) Dimepheptanol;
961.14(2)(jm) (jm) Dimethylthiambutene;
961.14(2)(k) (k) Dioxaphetyl butyrate;
961.14(2)(km) (km) Dipipanone;
961.14(2)(m) (m) Ethylmethylthiambutene;
961.14(2)(mm) (mm) Etonitazene;
961.14(2)(n) (n) Etoxeridine;
961.14(2)(nc) (nc) 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
961.14(2)(ne) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).
961.14(2)(nm) (nm) Furethidine;
961.14(2)(p) (p) Hydroxypethidine;
961.14(2)(pm) (pm) Ketobemidone;
961.14(2)(q) (q) Levomoramide;
961.14(2)(qm) (qm) Levophenacylmorphan;
961.14(2)(qs) (qs) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- piperidinyl]-N-phenylpropanamide);
961.14(2)(r) (r) Morpheridine;
961.14(2)(rg) (rg) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
961.14(2)(rj) (rj) 3-methylthiofentanyl (N-{3-methyl-1-[2-(2-thienyl)ethyl]-4-piperidinyl}-N-phenylpropanamide);
961.14(2)(rm) (rm) Noracymethadol;
961.14(2)(s) (s) Norlevorphanol;
961.14(2)(sm) (sm) Normethadone;
961.14(2)(t) (t) Norpipanone;
961.14(2)(tg) (tg) Para-fluorofentanyl (N-[1-(2-phenylethyl)-4-piperidinyl]-N-(4-fluorophenyl)propanamide);
961.14(2)(tm) (tm) Phenadoxone;
961.14(2)(u) (u) Phenampromide;
961.14(2)(um) (um) Phenomorphan;
961.14(2)(v) (v) Phenoperidine;
961.14(2)(vg) (vg) PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine);
961.14(2)(vm) (vm) Piritramide;
961.14(2)(w) (w) Proheptazine;
961.14(2)(wm) (wm) Properidine;
961.14(2)(wn) (wn) Propiram;
961.14(2)(x) (x) Racemoramide;
961.14(2)(xm) (xm) Thiofentanyl (N-{1-[2-(2-thienyl)ethyl]-4-piperidinyl}-N-phenylpropanamide);
961.14(2)(xr) (xr) Tilidine;
961.14(2)(y) (y) Trimeperidine.
961.14(2)(z) (z) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide).
961.14(3) (3)Substances derived from opium. Any material, compound, mixture or preparation which contains any quantity of any of the following substances derived from opium, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:
961.14(3)(a) (a) Acetorphine;
961.14(3)(b) (b) Acetyldihydrocodeine;
961.14(3)(c) (c) Benzylmorphine;
961.14(3)(d) (d) Codeine methylbromide;
961.14(3)(e) (e) Codeine-N-oxide;
961.14(3)(f) (f) Cyprenorphine;
961.14(3)(g) (g) Desomorphine;
961.14(3)(h) (h) Dihydromorphine;
961.14(3)(hm) (hm) Drotebanol;
961.14(3)(j) (j) Etorphine, except its hydrochloride salts;
961.14(3)(k) (k) Heroin;
961.14(3)(m) (m) Hydromorphinol;
961.14(3)(n) (n) Methyldesorphine;
961.14(3)(p) (p) Methyldihydromorphine;
961.14(3)(q) (q) Morphine methylbromide;
961.14(3)(r) (r) Morphine methylsulfonate;
961.14(3)(s) (s) Morphine-N-oxide;
961.14(3)(t) (t) Myrophine;
961.14(3)(u) (u) Nicocodeine;
961.14(3)(v) (v) Nicomorphine;
961.14(3)(w) (w) Normorphine;
961.14(3)(x) (x) Pholcodine;
961.14(3)(y) (y) Thebacon.
961.14(4) (4)Hallucinogenic substances. Any material, compound, mixture or preparation which contains any quantity of any of the following hallucinogenic substances, including any of their salts, isomers, esters, ethers, and salts of isomers, esters, or ethers that are theoretically possible within the specific chemical designation, in any form contained in a plant, obtained from a plant, or chemically synthesized:
961.14(4)(a) (a) 3,4-methylenedioxyamphetamine, commonly known as “MDA";
961.14(4)(ag) (ag) 3,4-methylenedioxyethylamphetamine, commonly known as “MDE";
961.14(4)(am) (am) 3,4-methylenedioxymethamphetamine, commonly known as “MDMA";
961.14(4)(ar) (ar) N-hydroxy-3,4-methylenedioxyamphetamine;
961.14(4)(b) (b) 5-methoxy-3,4-methylenedioxyamphetamine;
961.14(4)(bm) (bm) 4-ethyl-2,5-dimethoxyamphetamine, commonly known as “DOET";
961.14(4)(c) (c) 3,4,5-trimethoxyamphetamine;
961.14(4)(cm) (cm) Alpha-ethyltryptamine;
961.14(4)(d) (d) Bufotenine;
961.14(4)(e) (e) Diethyltryptamine;
961.14(4)(f) (f) Dimethyltryptamine;
961.14(4)(g) (g) 4-methyl-2,5-dimethoxyamphetamine, commonly known as “STP";
961.14(4)(h) (h) Ibogaine;
961.14(4)(j) (j) Lysergic acid diethylamide, commonly known as “LSD";
961.14(4)(m) (m) Mescaline, in any form, including mescaline contained in peyote, obtained from peyote or chemically synthesized;
961.14(4)(mn) (mn) Parahexyl (3-hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo(b, d)pyran);
961.14(4)(n) (n) Phencyclidine, commonly known as “PCP";
961.14(4)(p) (p) N-ethyl-3-piperidyl benzilate;
2015-16 Wisconsin Statutes updated through 2017 Wis. Act 58 and all Supreme Court and Controlled Substances Board Orders effective on or before September 20, 2017. Published and certified under s. 35.18. Changes effective after September 20, 2017 are designated by NOTES. (Published 9-20-17)